ADMA Biologics Inc (NASDAQ:ADMA) Expected to Post Quarterly Sales of $4.36 Million

Wall Street analysts expect ADMA Biologics Inc (NASDAQ:ADMA) to report $4.36 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for ADMA Biologics’ earnings. The lowest sales estimate is $2.50 million and the highest is $9.21 million. ADMA Biologics reported sales of $4.66 million during the same quarter last year, which indicates a negative year over year growth rate of 6.4%. The company is expected to issue its next earnings report on Friday, August 9th.

On average, analysts expect that ADMA Biologics will report full-year sales of $24.30 million for the current year, with estimates ranging from $18.80 million to $43.91 million. For the next fiscal year, analysts expect that the business will post sales of $59.92 million, with estimates ranging from $49.10 million to $82.19 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover ADMA Biologics.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.31) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.01. The firm had revenue of $3.53 million for the quarter, compared to analysts’ expectations of $2.96 million. ADMA Biologics had a negative net margin of 370.27% and a negative return on equity of 210.69%.

ADMA has been the topic of several research analyst reports. Oppenheimer set a $14.00 price target on shares of ADMA Biologics and gave the company a “buy” rating in a report on Tuesday, June 25th. HC Wainwright set a $7.00 target price on shares of Armata Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, May 23rd. Jefferies Financial Group assumed coverage on shares of ADMA Biologics in a research note on Tuesday, June 4th. They set a “buy” rating and a $8.00 target price for the company. ValuEngine raised shares of Yelp from a “sell” rating to a “hold” rating in a research note on Wednesday, April 3rd. Finally, Maxim Group set a $8.00 price target on shares of TrovaGene and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Nine analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of $11.17.

In related news, major shareholder Life Sciences Maste Perceptive acquired 4,000,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The stock was purchased at an average price of $4.00 per share, for a total transaction of $16,000,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Adam S. Grossman acquired 30,000 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The stock was bought at an average price of $4.00 per share, with a total value of $120,000.00. Following the transaction, the insider now directly owns 37,527 shares in the company, valued at $150,108. The disclosure for this purchase can be found here. In the last three months, insiders bought 4,064,500 shares of company stock worth $16,258,000. Insiders own 18.80% of the company’s stock.

Several institutional investors have recently modified their holdings of ADMA. Burns J W & Co. Inc. NY acquired a new position in ADMA Biologics during the first quarter worth $55,000. Diag Capital Management LP purchased a new position in ADMA Biologics in the fourth quarter valued at about $435,000. Geode Capital Management LLC boosted its holdings in ADMA Biologics by 14.4% in the fourth quarter. Geode Capital Management LLC now owns 276,930 shares of the biotechnology company’s stock valued at $661,000 after purchasing an additional 34,818 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in ADMA Biologics in the fourth quarter valued at about $34,000. Finally, United Services Automobile Association purchased a new position in ADMA Biologics in the fourth quarter valued at about $27,000. Institutional investors own 38.70% of the company’s stock.

ADMA Biologics stock remained flat at $$3.89 during trading hours on Friday. 554,289 shares of the company’s stock traded hands, compared to its average volume of 691,734. The company has a market cap of $224.08 million, a PE ratio of -2.68 and a beta of 2.71. The company has a debt-to-equity ratio of 5.70, a current ratio of 4.60 and a quick ratio of 2.39. ADMA Biologics has a 52-week low of $2.08 and a 52-week high of $6.96. The business’s 50 day moving average is $3.84.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

See Also: How does a margin account work?

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.